Research programme: cancer therapeutics - Oscotec

Drug Profile

Research programme: cancer therapeutics - Oscotec

Alternative Names: HIF 143

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Oscotec
  • Class
  • Mechanism of Action Epidermal growth factor inhibitors; Fms-like tyrosine kinase 3 inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (PO)
  • 31 Mar 2012 Preclinical trials in Cancer in South Korea (PO) before March 2013
  • 31 Mar 2012 Efficacy and toxicological data from preclinical trials in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top